Akebia Therapeutics, Inc.
Here’s whether Akebia Therapeutics, Inc. (AKBA) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: RSI 36 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-6.84% over 10 days); weak 1-year return of -74.7%; 3-month momentum negative (-38.8%). Currently 77.3% off its 52-week high. Score: -5/7.
AKBA is trading below its 200-day MA ($1.75) — a key warning sign the longer-term trend is under pressure. An RSI of 36.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -74.7% compares to +22.9% for SPY (trailed the market by 97.5%). The current 77.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.